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resumo 
 
 
A doença de Alzheimer (AD) é uma perturbação degenerativa multifatorial 
associada com a idade que ocorre no sistema nervoso central. Após a sua 
descrição inicial em 1907, numerosas teorias foram propostas para elucidar 
quais as principais causas associadas. A hipótese da inflamação tem sido 
recentemente reconhecida pela comunidade científica, uma vez que muitos 
estudos em modelos e doentes de Alzheimer propuseram fortes evidências da 
ativação do sistema imunológico e de processos inflamatórios durante o curso 
da doença. De facto, a acumulação de β-amilóide (Aβ) e proteína tau provocam 
uma resposta inflamatória cerebral como resultado do desenvolvimento 
patológico da AD. Atualmente, os estudos de associação genómica genética 
(GWAS) proporcionaram a identificação de diversas variantes genéticas que 
influenciam por exemplo processos inflamatórios e as vias do sistema imunitário 
na AD, estando as regiões polimórficas CLU rs11136000 e CR1 rs3818361 entre 
elas. Além disso, ambos os polimorfismos de um único nucleótido (SNPs) 
parecem ter um papel colaborativo relativamente à eliminação de Aβ e à 
ativação do sistema imunitário através da estimulação do complemento. 
No trabalho aqui descrito, foram realizadas análises bioinformáticas de genes 
de risco para a AD, principalmente o CLU e o CR1. As informações obtidas foram 
usadas para criar uma rede de interação proteína-proteína, bem como para 
realizar análises de enriquecimento de Ontologia Genética. A nossa análise 
bioinformática indica que ambos os genes CLU e CR1 estão envolvidos numa 
variedade de vias de sinalização que compreendem a regulação do processo 
inflamatório e ativação do sistema imunológico. 
A expressão genética de cada alelo de risco das SNPs CLU rs11136000 e CR1 
rs3818361 foi ainda avaliada em amostras de doentes “Putativos AD” e 
Controlos por testes de PCR e análises de sequenciação de Sanger. 
Adicionalmente, as frequências genotípicas e alélicas também foram 
determinadas com o intuito de criar um perfil genético dos grupos estudados. 
Os nossos resultados demostraram que no grupo de doentes “Putativos AD” 
analisado para a variante CLU rs11136000, o alelo de risco C apresentou maior 
frequência (64%) quando comparado com o grupo Controlos (40%). O grupo de 
Controlos apresentou uma frequência de 60% para o alelo de não-risco. Para a 
variante CR1 rs3818361, o alelo de risco A apresentou frequências semelhantes 
entre grupos, apesar do aumento da percentagem de homozigóticos de risco 
(6%) no grupo de doentes “Putativos AD”. 
Este trabalho auxilia na compreensão da relação entre estes polimorfismos 
genéticos e demência. Estudos adicionais devem avaliar o uso destas SNPs 
como ferramentas potencialmente úteis no diagnóstico da AD. 
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abstract 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alzheimer’s disease (AD) is a multifactorial age associated degenerative 
disorder that occurs in the central nervous system. After its initial report in 1907, 
numerous theories have been proposed to elucidate on what are the related main 
causes. The inﬂammation hypothesis has been recently acknowledged by the 
scientific community since several studies in AD models and patients strongly 
supported the activation of the immune system and of inﬂammatory processes 
during disease development. In fact, the accumulation of amyloid-β (Aβ) and tau-
neurofibrillary tangles provokes a brain inﬂammatory response as a 
consequence of the pathological development of AD. Currently, genome-wide 
association studies (GWAS) have provided several genetic variants that impact 
inflammation and immune system pathways in AD, being the polymorphic 
regions CLU rs11136000 and CR1 rs3818361 among them. Furthermore, both 
single-nucleotide polymorphisms (SNPs) appear to have a collaborative role 
regarding Aβ clearance and immune system activation via complement 
stimulation. 
In the work here described, bioinformatics analyses of AD risk-related genes, 
focusing on CLU and CR1 were performed and the retrieved information used to 
rise a protein-protein interaction network, as well as to perform Gene Ontology 
enrichment analyses. Our bioinformatics analysis indicates that CLU and CR1 
are involved in a variety of signaling pathways that comprise activation and 
regulation of immune system process. 
CLU rs11136000 and CR1 rs3818361 genetic expression of each SNP risk allele 
was further evaluated in whole blood samples from “Putative AD” and Controls 
groups by PCR assays and Sanger sequencing analyses. Additionally, the 
genotyping and allelic frequencies were also determined in order to create a 
genetic profile of the studied groups. 
Our results showed that on the “Putative AD” group analyzed for CLU 
rs11136000 variant, the C-risk allele presented a higher frequency (64%) when 
compared to Controls (40%). The Controls group displayed a 60% frequency for 
the non-risk allele. For the CR1 rs3818361 variant, the A-risk allele showed 
similar frequencies among groups, although an increase in the percentage of 
homozygous risk carriers (6%) was observed in the “Putative AD” group.  
This work aids into the understanding of the relation between these genetic 
polymorphisms and dementia. Additional studies should address the use of these 
SNPs as potential tools in AD diagnostics. 
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 Introduction  
  Alzheimer’s disease and its neuropathological hallmarks  
Alzheimer’s disease (AD) is the primary form of age-related neurodegenerative 
dementia, which embodies an emerging global health crisis. In 2015, an estimated 46.8 million 
people worldwide lived with dementia, and the majority of these were diagnosed with AD 
(Figure 1) 1,2. 
 
  
 
 
 
 
 
 
 
 
 
This amount will nearly double every 20 years, reaching 74.7 million in 2030 and 131.5 
million in 2050. The fastest expansion in the elderly population is occurring in China, India, and 
their south Asian and western Pacific neighbors. Recent data showed that over 153000 people 
in Portugal have dementia, 90000 of AD type. In other words, at least 1% of the Portuguese 
population has been diagnosed with this illness, representing a striking impact on the national 
public health system1,3. 
AD was first described in 1907 by a Bavarian psychiatrist with expertise in 
neuropathology named Alois Alzheimer, regarding his observations in a 51-year-old patient, 
Figure 1: Expected number of people with dementia until 2050, 
according to the World Alzheimer Report of 2015. This analysis 
shows that high income countries have more affected individuals 
with dementia compared to low and middle income countries. 
Nevertheless, both will have a strong increase in the next 34 
years. From1. 
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Auguste D. Her symptoms included short-term memory loss, unusual behavior and 
neuropathological characteristics, that later became recognized as the hallmarks of the disease4. 
The initial symptoms of this disease are frequently mistaken as part of standard aging 
processes, or indicators of stress. With AD development, symptoms may comprise aggression, 
irritability, confusion, and language problems, as well as loss of long-term memory and 
ultimately death5. 
Neuropathological alterations are represented by loss of neurons and synapses in the 
cerebral cortex and certain subcortical regions, resulting in gross atrophy of the affected areas 
and degeneration of specific brain areas, including temporal and parietal lobes and parts of the 
frontal cortex and cingulate gyrus5. Magnetic resonance imaging (MRI) and positron emission 
tomography (PET) techniques reveal specific atrophied brain regions, predominantly in the 
entorhinal cortex, the hippocampus and the temporal cortex, as patients followed the typical 
disease development stages: from asymptomatic, to mild cognitive impairment (MCI), and 
finally AD6,7.  
Certainly, the clinical development of AD is diverse and there are numerous features 
adding to the typical neuropathological extracellular senile plaques and neurofibrillary tangles 
(NFTs). Senile plaques, which are also known as amyloid plaques, consist of extracellular 
deposits of amyloid beta (Aβ) peptide, mainly represented by Aβ40, and Aβ42.  
Aβ peptides derive from the proteolytic processing of amyloid precursor protein (APP), 
which represents an integral membrane protein with extensive expression through the body8. 
Moreover, is mostly concentrated in neuronal synapses and it is associated with neurite 
extension and synaptic plasticity.  By contrast, NFTs are intracellular lesions entailing structures 
of paired helical filaments composed of hyperphosphorylated tau protein8. The latter is 
expressed predominantly in neurons, and it is responsible for microtubules stabilization and 
axonal transport (Figure 2)8.  
 
 
DCM/UA 2016 
 
Testing a dementia risk group for polymorphisms in inflammation-related 
genes   3 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amyloid markers, such as cerebrospinal fluid (CSF) Aβ42 and PET amyloid tracer uptake 
are the primary modifications of AD progression, nonetheless they reach a plateau level by the 
MCI stage. On the other hand, functional and metabolic markers are identifiable by task-
dependent stimulation on functional MRI and 18F-fluorodeoxyglucose PET, being unusual 
indicators for the MCI stage, and continuing to alter going into the dementia stage. The final 
structural alterations are followed by a temporal pattern that is associated with increased tau 
pathology accumulation (Figure 3)7. 
 
Figure 2: Alzheimer disease and the associated morphological alterations in the brain.  
This image shows gross and microscopic differences between normal and Alzheimer 
brain. It is possible to observe that the specific areas regarding the language and the 
memory are affected in the brain cross-sections in Alzheimer, compared to normal 
brain, which ultimately leads to cortical atrophy. Additionally, there are microscopic 
accumulations of intraneuronal neurofibrillary tangles, interstitial amyloid neuritic 
plaques and loss of neurons with gliosis in Alzheimer compared to normal brain. From9. 
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 Genetics of Alzheimer’s disease and Genome-wide association studies 
(GWAS) 
Epidemiological research discovered several risk factors for AD, mainly divided into vascular 
(such as, smoking, obesity, dyslipidemia, diabetes, hypertension and asymptomatic cerebral 
infarction), psychosocial (such as lower education, poor social engagement and physical activities) 
and genetic factors8. The latter has, in fact, a notorious role in AD and positive family history is a 
solid risk factor. Studies on identical twins established a high heritability for AD, being about 58% 
to 80%8. 
Therefore, AD is characterized by two forms centered on genetic features, namely, early-
onset familial Alzheimer’s disease (EOAD) and late-onset Alzheimer’s disease (LOAD)10,11,12. The 
familial EOAD form is inherited by Mendelian genetic distribution in an autosomal dominant pattern 
and the usual age of onset is typically before 6013. The loci of causative genetic mutations include 
the APP gene (located in chromosome 21) and the Presenilin-1 (PSEN1) and Presenilin-2 (PSEN2) 
Figure 3: The expected evolutionary model of cognitive and biological markers of AD. 
Abbreviations:  AD, Alzheimer disease; MCI, mild cognitive impairment; NINCDS–ADRDA, 
National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer's 
Disease and Related Disorders Association. From 7. 
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genes (located on chromosomes 14 and 1, respectively), all of which have complete penetrance10. 
The EOAD genes mutations and their molecular phenotypes on AD patients, such as increase Aβ 
formation and aggregation are summarized in Table 114. 
 
Table 1. EOAD genes and their pathogenic effects on Alzheimer disease. 
Gene Protein Chromosome Molecular Phenotype 
APP Amyloid-β 
protein 
percursor 
21q21 Increased Aβ42/Aβ40 ratio 
Increased Aβ production 
Increased Aβ aggregation 
PSEN1 Presenilin -1 14q24 Increased Aβ42/Aβ40 ratio 
PSEN2 Presenilin -2 1q31 Increased Aβ42/Aβ40 ratio 
 
 
On the other hand, LOAD covers more than 90% of AD patients, and still lacks a well- defined 
way of transmission15. This form shows a genetically complex pattern of inheritance of joint 
mechanism between genetic risk factors, aging, environmental factors and life exposure events, 
that together regulate lifetime risk for AD16. Furthermore, APOE (apolipoprotein E) gene, which 
encodes the APOE protein, has been established as a major risk factor for LOAD17,18 and has an 
important role in mediating cell signaling, synaptic plasticity, neuroinflammation (inflammation in 
the central nervous system (CNS)), as well as in cholesterol and lipid transport20. APOEε4 (APOE 
allele 4) amplifies the risk of AD in Caucasians and Asians populations and individuals with two 
APOEε4 alleles have 15 to 17 times higher risk to AD than those lacking this allele21,22. Nevertheless, 
the APOE genotype describes merely 20% of AD risk20.  
Although EOAD mutations led to AD, APOEε4 allele represents a genetic risk factor for LOAD 
by increasing the age of onset in a dose-dependent manner and it is not a direct cause for AD 
development.  Subsequently to the initial studies of APOE as a genetic risk factor for LOAD, 
hundreds of genes have been published with an association to AD, making it difficult to track and 
analyze the available data.  
Currently, the best approach to search for new AD genes has been the genome-wide 
association study (GWAS). Several GWAS reports have identified many genes (Table S1, Appendix 
1) based on numerous genetic markers as single nucleotide polymorphisms (SNPs) to find the 
genetic association with disease risk and/or endophenotypes such as age-of-onset, biomarkers, 
imaging results and neuropathological endpoints16.  
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These genes are associated with numerous biological processes, including cell migration, 
lipid transport and endocytosis, amyloidogenesis, tauopathy, synaptic and cytoskeletal function, 
and are also related to immunological mechanisms and neuroinflammation23 (Figure 4).  
 
 
 
 
Figure 4: Rare and common variants contribute to Alzheimer’s disease risk from GWAS. This 
illustration shows the association between the frequency of these rare and common variants in the 
population obtained from GWAS with the risk of developing Alzheimer’s disease. The variants can be 
evaluated in a progressive scale going from low risk to medium and high risk. Additionally, the 
variants are illustrated in different colors according to their respective biologic function. 
Abbreviations: ADAM10, disintegrin and metalloproteinase domain-containing protein 10; APP, 
amyloid precursor protein; PS1, presenilin-1; PS2, presenilin-2; APOE4, apolipoprotein E4; BIN1, myc 
box-dependent-interacting protein 1; CD2AP, CD2-associated protein; EPHA1, ephrin type-A receptor 
1; MS4A6A, membrane-spanning 4-domains subfamily A member 6A; CLU, clusterin; CR1, 
complement receptor-1; PICALM, phosphatidylinositol-binding clathrin assembly protein; ABCA7, 
ATP-binding cassette sub-family A member 7; CD33, myeloid cell surface antigen CD33; HLA-DRB1, 
HLA class II histocompatibility antigen, DRB1-1 beta chain; HLA-DRB5, HLA class II histocompatibility 
antigen, DR beta 5 chain; PTK2B, protein-tyrosine kinase 2-beta; SORL1, sortilin-related receptor; 
SLC24A4, sodium/potassium/calcium exchanger 4; RIN3, ras and rab interactor 3; DSG2, desmoglein-
2; INPP5D, phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1; MEF2C, myocyte-specific 
enhancer factor 2C; NME8, thioredoxin domain-containing protein 3; ZCWPW1, zinc finger CW-type 
PWWP domain protein 1;  NYAP1, neuronal tyrosine-phosphorylated phosphoinositide-3-kinase 
adapter 1; CELF1, CUGBP Elav-like family member 1; FERMT2, fermitin family homolog 2; CASS4, cas 
scaffolding protein family member 4; PLD3, phospholipase D3; TREM2, triggering receptor expressed 
on myeloid cells 2. From24. 
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GWAS use genotyping shared ancestral polymorphisms that typically arise in 0.5% of the 
overall population16. Even though a large amount of the genetic variance of LOAD continues 
inexplicable, several loci containing genetic variants inﬂuencing both immunological response and 
inﬂammatory pathways in AD patients have been identiﬁed by GWAS.  Among these new genes are 
Clusterin (CLU) located on chromosome 8, which is a powerful regulator of complement activation 
and Complement receptor-1 (CR1) placed on chromosome 1, which is a vital player on immune 
system. These genes both participate in Aβ clearance, and both are major players within 
inﬂammatory response that is activated as part of the brain’s innate immune system in AD (Figure 
5)16,25. CLU rs11136000 and CR1 rs3818361 SNPs were reported to contribute for AD pathogenesis, 
with both variants having a strong risk for LOAD26,27. CLU and CR1 involvement in AD will be further 
discussed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Genetic risk factors and inflammation in AD. This representation shows the 
association among innate immunity-related genetic risk factors and inflammation-inducing 
events (brain trauma, ischemia and infection) that influence the multifactorial etiology of LOAD. 
Both delirium and dementia encode a neuroinflammatory response that may describe the 
vulnerability of AD patients to additional cognitive deterioration. Subsequently, this response 
provokes a delirium occurrence related to a systemic inflammatory reaction. Abbreviations: Aβ, 
amyloid-β peptide; AD, Alzheimer’s disease; APOE4, apolipoprotein E4; APP, amyloid precursor 
protein; CLU, clusterin; CR1, complement receptor-1; PS1, presenilin-1; PS2, presenilin-2. 
From25. 
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The genetic findings on the etiology and pathogenesis of AD will continue to improve our 
knowledge on the pathological mechanisms underlying AD. Additionally, the search for further rare 
sequence variants in genes that prompt AD development will also aid in this understanding. 
Ultimately, these discoveries will support the development of new therapeutic approaches for 
preventing, stopping and even reversing AD course27. 
 Inflammation and immune response in Alzheimer’s disease 
Many studies confirmed the presence of immune-related antigens and cells around amyloid 
plaques in the brains of individuals with AD, in addition to Aβ and tau protein aggregates28. Several 
evidences support the involvement of inflammation and immune responses in the pathogenesis of 
psychiatric disorders such as dementia, depression, and schizophrenia29. The pathogenesis of AD is 
also affected by immunological and inflammation mediated mechanisms. In the 1990s, studies 
addressing the activated complement factors, cytokines and a wide range of receptors in the brain 
of AD patients confirmed the association between immunological and inflammatory courses with 
this disease and that immune system-mediated activities promote AD pathogenesis30,31.   
 
 Aβ and Neuroinflammation 
As previously described, the two main pathological hallmarks for AD, namely Aβ plaques 
and NFTs, are key players in AD course. According to the amyloid cascade hypothesis, Aβ 
accumulation in the brain — resulting from aberrant processing of APP or dysfunctional clearance 
of Aβ peptide — is the initiating event in AD. Additionally, every EOAD related mutation influences 
the formation or aggregation predisposition of the Aβ peptide. In fact, the majority of cases 
regarding EOAD are triggered by dominant genetic mutations, mainly inked to the PSEN1 and PSEN2 
proteins, that constitute part of the γ-secretase complex involved in the proteolytic process of APP8.  
Furthermore, the cleavage of APP occurs by two main ways: the non-amyloidogenic or the 
amyloidogenic pathway, although just the later leads to Aβ formation. 
In the non-amyloidogenic via, that precludes Aβ formation, APP is initially cleaved by α-
secretase, which generates a soluble N-terminal ectodomain named secreted amyloid precursor 
protein-α (sAPPα) - that is release from the cell surface -, and a truncated APP C-terminal fragment 
(CTF) (αCTF or C83). This fragment is subsequently cleaved by γ-secretase, leading to the secretion 
of a small non-pathogenic peptide p3 and a free APP intracellular domain (AICD), which is released 
into the cytosol32. On the other hand, in the amyloidogenic pathway, the β-secretase initiates Aβ 
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generation by shedding a large part of the ectodomain of APP (sAPPβ) and generating an APP CTF 
(βCTF or C99). This fragment is then cleaved by γ-secretase, generating Aβ and AICD. This final 
cleavage regulates the formation of the predominant Aβ40 or the more aggregation-prone and 
neurotoxic Aβ42 species (Figure 6)32,33.  
 
 
 
 
 
 
 
 
 
 
 
The amyloidogenic pathway products are the main pathological findings in AD35. Numerous 
(soluble and insoluble) species and aggregation states of Aβ peptide can occur, comprising 
monomers, oligomers, protofibrils, fibrils and Aβ plaques. Further, the latest understandings about 
their biology indicate that these forms most likely have variable levels of pathogenic effects. 
Genetic findings sustain the hypothesis that atypical formation or increase of Aβ is a pathogenic 
feature in both EOAD and LOAD8 and reports confirmed the development of Aβ pathology on 
transgenic mice with human APP mutations, as well as in cell lines36,37.  
Additionally, the presence of Aβ can instigate microglial cells, which are the local 
macrophages of the CNS. These are the main cellular foundations of the innate immune system, 
not only by promoting the homeostasis regulation of other cells such as astrocytes and neurons in 
the CNS38,39, but also by remodeling the brain being involved in the removal of apoptotic neurons 
and the reduction of tissue impairment40,41.  
Figure 6: APP proteolytic processing. APP processing involves proteolytic cleavage 
by several secretases. The amyloidogenic pathway releases Aβ peptides through 
cleavage by β- and γ-secretases. The non-amyloidogenic pathway is initiated by α-
secretase cleavage, which cuts the middle of the Aβ domain, resulting in the release 
of several soluble APP fragments. Abbreviations: Aβ, β-amyloid; APP-CTF, APP C-
terminal fragment; AICD, APP intracellular domain. Reproduced from34. 
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Microglia ensure the adequate examination of their local microenvironment and protection 
by attacking pathogens via phagocytosis, generation of cytokines, oxyradicals, and initiation of the 
complement cascade42. Additionally, these CNS cells may also induce neural development, 
influence vascular growth and dissipate toxic senile plaques by phagocytosis43. Microglia can 
destroy soluble Aβ peptides via proteolytic degradation in endolysosomal compartments44 and 
sphingolipid-modulated exosomes can activate microglia-mediated clearance of Aβ45. Conversely, 
senescence of microglia and failure to correctly transform the microglial phenotype could impact 
the success of microglial amyloid clearance46,47,48. 
In AD, Aβ endures chronic activation of stimulated microglia (due to the peptide’s 
accumulation), which produces a continuous level of inflammatory cytokines, chemokines, reactive 
oxygen and nitrogen species. In addition, these substances are responsible for preserving the 
activation of the stimulated cells, further discussed. Consequently, this mechanism leads to a 
vicious loop that eventually damages microglia. This damage also results from affected adjacent 
resident cells of the CNS, such as astrocytes, oligodendrocytes and neurons, and perhaps 
aggravated tau pathology as well, which lastly causes neurodegeneration and neuron loss. 
Moreover, if these courses extend over a continued period, it compels the microglia cells into a 
senescent, ‘burn-out’-like (dystrophic) phenotype, which is assumed to be permanent (Figure 7)49. 
The amyloid cascade hypothesis supports a crucial pathogenic role for Aβ, a fundamental 
neurotoxic peptide in AD50. Immunological machinery and neuroinflammation triggered by A have 
likewise a critical role in AD development51,52. 
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Clustered microglia and fibrous astrocytes surrounding extracellular deposits of Aβ plaques 
were mentioned in various publications. The accumulation of Aβ peptides, particularly aggregation-
prone Aβ42 species, foment the formation of amyloid fibrils and Aβ oligomers in AD. Misfolded Aβ 
peptides can generate chemokines and similarly have a direct role as microglial attractants. For 
instance, chemokine receptors such as C-C chemokine receptor type-2 (CCR2), C-C chemokine 
receptor type-3 (CCR3), C-C chemokine receptor type-5 (CCR5), and CX3C chemokine receptor-1 
(CX3CR1) exist in the microglia and brain of AD patients, and CXC chemokine receptor-2 (CXCR2) 
and CXC chemokine receptor-3 (CXCR33) are within the proximity of neuritic plaques53. 
Microglia are not only observed within amyloid plaques, but they also connect to Aβ 
oligomers and Aβ fibrils by cell surface receptors, such as cluster of differentiation (CD) CD3654, 
integrin-associated protein (IAP)/CD-47, α6β1 integrin55, scavenger receptor A-1 (SCARA1)56, Toll-
like receptors (TLRs)57 and associated receptors (e.g., CD14)58. In fact, the association between 
receptor and Aβ fibrils promotes the in vitro phagocytosis by microglia cells of Aβ fibrils and the 
destruction of soluble Aβ species via extracellular proteases, neprilysin, and insulin-degrading 
Figure 7: Microglial phenotypes prompted by Aβ. Generation of different microglia phenotypes 
stimulated by Aβ and other pathological protein deposits (alterations in the CNS, systemic or 
local inflammation, and mutations in genes encoding innate immune molecules). This process 
leads towards the formation of inflammatory cytokines and chemokines, that ultimately causes 
neurodegeneration, neuron loss and probably intensified tau pathology. From49. 
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enzyme (IDE)59. Successively, the connection of CD36 and TLRs 4 and 6 with Aβ peptides contribute 
to the generation of proinflammatory cytokines and chemokines by microglia60. 
Additionally, the complement system, a crucial feature of the innate immune system, 
comprises anaphylatoxins and opsonins, essential for Aβ clearance. In fact, genetic removal of 
complement factor C3 in mice has shown to increase Aβ deposition and neurodegeneration61. The 
assembly of proteins from the complement system is also one role of microglia cells and astrocytes 
and reduced clearance of Aβ peptides by microglia adds to the pathogenesis of AD.  
Chronic microglial activation is present in AD pathogenesis. For example, a positive 
feedback loop among inflammation and increased Aβ production leads to chronic, non-resolving 
inflammation62,63. Chronic inflammation leads to massive and continued release of 
proinflammatory cytokines, chemokines, and other inflammation mediators. This process 
contributes to neuroinflammation and consequently to neuronal impairment. High levels of 
proinflammatory cytokines such as TNFα versus low levels of anti-inflammatory cytokine TGF-β 
induced the progression of dementia from MCI to AD64. Furthermore, microglial stimulation and 
inflammatory reactions lead to activation of mitogen-activated protein kinase (MAPK) and 
intensifies hyperphosphorylation of tau protein in mouse models63,65. Cytokine-release impacts on 
tau pathology, affects neuronal transport and injures neurons66. 
On the other hand, microglia activation elevates nitric oxide (NO) and reactive oxygen 
species (ROS) production. In turn, ROS and reactive nitrogen species (RNS) can disrupt proteins, 
lipids, carbohydrates, deoxyribonucleic acid (DNA), and ribonucleic acid (RNA), which causes several 
forms of injury including cell death67. Oxidative stress can also intensify Aβ production and 
aggregation process68. Additionally, inducible nitric oxide synthase (iNOS) is expressed in the brain 
of patients with AD, and its genetic removal in mice is protective regarding AD course69. 
Like microglia, astrocytes have a rapid reaction towards pathology, altering their 
morphology, antigenicity, and activity70. Astrocytes have an indispensable neuro-supportive role in 
the brain and their functions include the release and reutilization of transmitters, ion homeostasis, 
energy metabolism control, synaptic remodeling, and modulation of oxidative stress. In fact, the 
disturbance of the neuro-supportive astrocyte features has highly damaging magnitudes for the 
CNS71. 
Responsive astrocytes reside in peri-plaque areas of the brain in AD patients and in AD 
transgenic mouse models, with a characteristic form that resonant glial scarring - a mechanism by 
which the cells deliver a barrier among healthy tissue and areas of injury or infection72. The MCP1 
(Monocyte chemoattractant protein-1 (MCP-1/CCL2)) chemokine is prominently concentrated in 
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Aβ plaques and acts as chemotactic for adult astrocytes. These astrocytes express receptors that 
associates with Aβ, including low density lipoprotein receptor-like protein, membrane-associated 
proteoglycans, and scavenger receptor-like receptors. Such system is responsible for the high 
accumulation of reactive astrocytes situated within Aβ deposits72. 
Additionally, numerous studies concluded that plaque-localized, responsive astrocytes can 
degrade Aβ peptides73. Moreover, in Tg2576 transgenic mice this feature is related to insulin 
degrading enzyme (IDE), crucial for Aβ degradation. IDE levels are higher in immunoreactive 
astrocytes around Aβ deposits74. 
Astrocyte secretion of matrix metalloproteinases may also play a key role in extracellular 
clearance of Aβ75. Aβ disturbs astrocyte calcium homeostasis76 and elevates GFAP, a process 
associated with degeneration of neurons in astrocyte-neuron co-cultures77. Responsive astrocytes 
induce neuropathology via expression or overexpression of several of inﬂammation-related factors. 
For instances, S100 calcium-binding protein-b (S100b), a neurotropin that promotes neurite 
growth, is overexpressed in AD brain, due to countless dystrophic neurites within Aβ deposits78. 
Further, Aβ can also lead to IL-1β, TNF-α, iNOS, and NO formation in astrocytes79. 
Most of these results may be suggestive of modifications regarding astrocyte transcription 
factors. The proinﬂammatory cytokines IL-1β, IL-6, and TNF-α are regulated by nuclear kappa-B (NF-
kB) and CCAAT-enhancer-binding proteins (C/EBP) transcription factors. Astrocyte NF-kB is also 
induced upon Aβ exposure, which augments IL-1β and IL-6 levels. Hence, the release of chemokines 
and adhesion molecules in astrocytes can be regulated by NF-Kb mechanisms, which possibly allows 
the incursion of peripheral leukocytes and adds to an inﬂammatory reaction in the brain80. 
 
 Immunity effects 
The microglial activation process is very diverse and certainly influences the evolution of 
neurodegenerative diseases81.  
Infiltrated blood macrophages from periphery and perivascular macrophages have an 
important role in the pathogenesis of AD82. For instance, activated perivascular macrophages 
decrease the cerebral amyloid angiopathy and Aβ deposition in cerebral blood vessels and 
leptomeninges in a mouse model of AD83, an event involving the CCR2 chemokine, that is crucial for 
Aβ clearance by perivascular macrophages84. Indeed, elevated infiltration levels from peripheral 
macrophages were reported in the CNS of AD model mice85, which may partly contribute to Aβ 
clearance. 
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Several in vitro studies of oligodendrocyte toxicity has been described for Aβ25-3586, 
Aβ4086,87, and Aβ4288. Oligodendrocytes express mRNAs and show immunoreactivity towards 
complement components C1q, C1s, C2, C3, C4, C5, C6, C7, C8, and C9. This fact proposes that these 
may possibly be a major cause for complement augmentation in pathologically-vulnerable areas of 
the AD brain89. Complement stimulation takes place on oligodendrocytes via C1q association to 
myelin oligodendrocyte protein and results from reduced levels of C1 inhibitor and membrane 
cofactor protein expressed by these cells.  
Aβ can also impact at the white blood cells. Aβ fibrils function as an altered self-antigen, 
improving Aβ specific T lymphocytes. Blood vessels contiguous to Aβ fibrils display elevated levels 
of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), 
which induces extravasation of stimulated Aβ specific T lymphocytes91.  
Additionally, the population of lymphocytes was shown to be altered in peripheral immune 
system with low levels of peripheral T and B lymphocytes in AD patients92. In particular advanced 
stages, it is possible to detect reduced levels of naive CD4+ T lymphocyte subpopulations, CD19+ B 
lymphocytes and naive B cells (immunoglobulin (Ig)-D+CD27−) and also increased double negative 
(IgD−CD27−) memory B cells detection. Further, a reduction of CD8+CD28− suppressor T 
lymphocytes and IL-10 production in AD was also reported, which suggests lower 
immunosuppressive skills93. 
In AD, chronic inflammation promotes the reduction of naïve lymphocytes and the 
expression of altered chemokine receptors in lymphocytes. Furthermore, the elevated expression 
of pro-inflammatory chemokine receptors, C-C chemokine receptor type 6 (CCR6) and C-C 
chemokine receptor type 7 (CCR7) on B lymphocytes can contribute to chronic inflammatory 
condition94.  
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 Clusterin  
Clusterin (CLU) is an approximately 80kDa chaperone glycoprotein that can be dissociated 
in two 40kDa chains under reducing conditions. It is present in most of biological fluids95.  
The human CLU gene is located on chromosome 8 and contains 9 exons presented with 
numerous transcriptional isoforms95,96. The mature protein matches a secretory form of clusterin 
(sCLU), being a heterodimer with α and β subunits connected with five disulphide links. Individually, 
these subunit expresses three N-glycosylation locations with a carbohydrate heterogeneity, which 
improves the variety of glycoforms. In addition to sCLU that was initially identified, a nuclear form 
(nCLU) was described in human and murine cell lines exposed to many stress promoters such as 
radiations, heat shock, drugs, as well as in carcinoma cells. Furthermore, nCLU assembly was also 
observed in other conditions such as ethanol-induced cell death and hypoxia in the neonatal rodent 
brain97.  
Contrarily to sCLU cell survival effects, nCLU is related to cell death by apoptosis. The sCLU 
is extensively expressed in the body, being mostly secreted in CSF98. Elevated plasma clusterin in 
healthy centenarians (older than 105 years) suggests a potential function for this protein through 
longevity99. These mechanisms are still not completely understood, although additional reports 
acknowledged the involvement of other molecules that also function as binding ligands of sCLU 
such as complement factors, immunoglobulins, leptin, Aβ, alpha-synuclein (α-synuclein), prion 
protein, transforming growth factor beta (TGFβ)-receptors and stressed unfolded proteins100,101. 
 Clusterin in Alzheimer’s disease 
Clusterin is associated with lipid transport and metabolism, membrane protection, cell-cell 
interaction, apoptosis, and complement regulation. Regarding the complement system, clusterin 
controls the membrane attack complex and limits complement stimulation related to inflammatory 
reaction102.  
Under normal conditions, some neuronal subpopulations, particularly at the pontobulbar 
and spinal cord motor nuclei have high expression levels of CLU. Moreover, latest investigations in 
postmortem human brain reveled plenty populations of neurons expressing low levels of clusterin 
mRNA in the neocortex. CLU is also present within a few subpopulations of astrocytes, specifically 
over the hippocampal and in some neocortical subdivisions103. 
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Nowadays, it is known that CLU levels in the brain fluctuate throughout healthy aging. In 
line with this evidence significant age-related difference in clusterin expression expression were 
observed in glial cells 105. 
Reduced levels of CLU in high-density lipoproteins is linked to insulin resistance and obesity, 
which are also known risk factors for AD. In AD, several studies reported the co-localization of CLU 
in NFTs and extracellular Aβ deposits. Further, GWAS and meta-analyses indicated CLU as one of 
the LOAD susceptibility genes. These studies also described that increased clusterin plasma levels 
may be associated with brain atrophy, disease severity, and disease progression106.  
In AD, the CLU variants may obstruct the usual function of clusterin as a protective factor 
against oxidative stress, by inhibiting the normal role of clusterin as a sensor and chaperone of ROS.  
Among different reported SNPs the variant rs11136000 has a particular connection with plasma 
CLU levels and contributes to AD with similar genetic risk effects in both the Asian and Caucasian 
populations. The T-allele is assumed to be associated with reduced risk in AD development and 
better cognitive performance, whereas the C-allele represents a risk factor for AD development. It 
was reported that homozygous expression of the C-allele facilitates neural hyperactivity in frontal 
and posterior cingulate cortices as well as hippocampus, throughout a visual working memory task, 
a hyperactivation that at long term can be detrimental107,108,109. 
Furthermore, additional findings revealed reduced or even absent hippocampal–prefrontal 
connectivity during memory retrieval in AD patients and also in subjects suffering from MCI110. For 
the risk variant, a C-allele dosage-dependent variation of the efficient combination in hippocampus 
and prefrontal cortex during episodic memory tasks was observed applying genetic and imaging 
methods on healthy subjects (Figure 8)103.  
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Further reports showed altered white matter integrity in healthy carriers of the rs11136000 
risk variant, which translates to neurodevelopmental susceptibility111. Additionally, young healthy 
carriers of the C-allele presented a diminished fractional anisotropy, caused by myelin integrity loss 
rather than axonal injuries, using diffusion tensor MRI imaging. Microstructural alterations in long 
interhemispheric and intrahemispheric associations such as the corpus callosum, the fornix and the 
cingulum, are related to a prodromal vulnerability in AD112,113. 
As mentioned, individuals expressing the genotype related to greater risk (CC homozygous 
genotype) have higher neural activation in a task related network. A possible explanation would be 
that carriers of the protective T-allele would achieve an equivalent level of task performance, 
although with less brain stimulation and that greater cognitive effort is necessary in at-risk 
Figure 8: Altered functional coupling in carriers of rs11136000 risk variant for CLU. A: 
carriers of the C-risk allele reveal considerably reduced allele dosage-dependent 
coupling of the right dorsolateral prefrontal cortex (DLPFC) with the right hippocampus 
seed region through recall. Each red dot indicates size of effect in one subject and 
reproduces the connectivity among right DLPFC and right hippocampal seed area. B: 
carriers of the C-risk allele reveal considerably reduced allele dosage-dependent 
coupling of the right dorsolateral DLPFC with the left hippocampus seed region through 
recognition. Each red dot indicates size of effect in one subject and reproduces 
connectivity among the right DLPFC and the right hippocampal seed area Adapted 
from103. 
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individuals to complete equivalent levels of performance102. Moreover, additional reports 
described that carriers of this recently discovered rs11136000 AD risk variant of CLU, had 
longitudinal increases in neural activity resting state in brain regions critical to memory processes, 
in order to maintain their physiological function in cognitively normal at-risk individuals. Supporting 
these supposed compensatory boosts in neural response in some individuals may be the threshold 
beyond which primary cognitive damage initiates, setting their conversion from MCI to AD114. 
Increased hippocampal stimulation throughout memory processes in MCI individuals has also been 
observed in rs11136000 risk carriers, which may ultimately express earlier rates of decline in 
memory performance comparative to non-carriers at the pre-symptomatic stages of AD115,116. 
Besides, increased levels of CLU were identified on cerebrospinal fluid of AD patients, which 
may represent a relevant peripheral marker associated with disease development. 
In vitro and in vivo experimental models indicated a potential linkage between CLU and Aβ 
aggregation and clearance. Clusterin levels improve the degree of Aβ clearance and efflux via the 
blood brain barrier117. Furthermore, extracellular sCLU mutually limits Aβ40 monomers aggregation 
and also the toxic and inflammatory effects of oligomers by sequestration previous to peptides 
degradation.  In addition, a recent meta-analysis demonstrates that sporadic coding variants 
affecting sCLU β-chain are mostly observed in AD118.  
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 Complement receptor-1 
Complement receptor-1 (CR1), also known as C3b/C4b receptor or CD35, is situated on 
chromosome 1q32 and encodes CR1 protein. It is associated with the complement response and is 
part of the regulators of the complement activation (RCA) family of proteins119.  
The largest production of complement proteins occurs in the liver, but is also highly present 
in the serum. Nevertheless, glial cells and neurons in the CNS can synthesize these proteins as well 
during injury and neurodegeneration120,121-125. 
The complement system identifies molecular arrangements on pathogens or molecular 
patterns associated with damaged tissues and dying cells. Recognition may occur via C1q or 
mannose binding proteins, which have collagen-like receptor binding domains, or over interfaces 
with the multifunctional protein C3. After being triggered, a cascade of several proteins from the 
complement pathway can attract and stimulate immune cells, amplify antigen-speciﬁc immune 
responses, induce phagocytosis, support complement-mediated cytolysis by the membrane attack 
complex (MAC), and control cell proliferation and differentiation120. 
Furthermore, both classical and alternative pathways activation can form catalytic 
multiproteins, namely the C3 convertases, producing two proteolytic C3 fragments: C3a, which is 
associated with inflammation and phagocyte recruitment, and C3b that could trigger the lytic 
pathway related to C5, C6, C7, C8, and C9, which ultimately generates MAC, C5b-9, and may induce 
cytotoxicity. This pathway also leads to C5a activation, an additional small proinﬂammatory 
peptide. Then, C3b binding to specific molecules, by a mechanism entitled opsonization, facilitating 
phagocytosis by a number of cells through their surface expression of complement receptors 
(Figure 9)111.  
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 Complement receptor 1 in Alzheimer’s disease 
Many polymorphisms for CR1 have been studied, demonstrating that SNPs may affect the 
expression of CR1 molecules on the cell surface119. In AD, these SNPs on CR1 are reported to be 
associated with greater risk for disease development120. In fact, Aβ can activate the complement 
system121 and large GWAS confirmed that rs3818361 within the CR1 locus is associated with LOAD 
susceptibility in Caucasians122. The relationship between CR1 markers and LOAD in European and 
American population is additionally confirmed by associations between disease and the rs3818361 
variant26,27. This variant is also associated with neuroimaging measures and neuritic plaques burden 
in AD brains. 
Studies have explored inter-group variances in brain amyloid burden among risk (AG 
heterozygous genotype/AA homozygous genotype) and non-risk (GG homozygous genotype) 
carriers of the AD rs3818361 SNP in CR1 gene. Recent GWAS results showed a larger risk in carriers 
of the A-risk allele of this SNP in AD individuals. Significantly greater variance in brain amyloid 
deposition was observed in the non-risk group (GG homozygous genotype), which appeared to be 
associated in part with APOE genotype120. Consequently, GG homozygous genotype and APOE ε4 
carriers had more amyloid deposition in numerous brain areas, comparative to APOEε4 non-
carriers.  
 
Figure 9: Schematic interaction of the complement system 
components. Abbreviations: complement proteins, C1q, C3, C3b, 
C3a, C5, C5a, C5b, C6, C7, C8, C9; membrane attack complex, 
MAC. From111. 
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Although the CR1 A-risk allele was linked to reduced fibrillar amyloid in non-demented 
individuals, these authors have also observed elevated brain amyloid levels in carriers of the 
APOEε4 allele relative to non-carriers in cognitively normal older individuals120. Additional studies 
confirmed that individuals expressing GG homozygous genotype and APOEε4 positive results 
exhibited reduced episodic memory, which is a common endophenotype of LOAD. This indicates 
that there is a greater susceptibility for AD development in individuals caring both the risk variant 
rs3818361 and the APOEε4 allele26.  
Additionally, CR1 is pointed as a vital AD susceptibility gene, since the expression of 
complement factors are upregulated in affected regions of AD brains126.  
CR1 protein regulates the complement activity and high complement cascade activity can 
exacerbate AD pathology. Essentially, the presence of CR1 on phagocytic cells induces them to 
phagocyte specific particles, by stimulating the complement reaction. Of note, high CR1 expression 
levels are related to elevated cognitive deterioration in AD. Further, Aβ clearance in the brain is 
associated with CR1 expression127. Clearance of plasma Aβ42 is dependent on binding of CR1, which 
therefore leads to glial activation, ultimately promoting neural degradation and chronic 
inflammatory cascade activation127,128. CR1 protein expression may modulate microglia, leading to 
an amplified clearance rate of immune complexes129. Since genetic variance in CR1 modifies the 
volume of Aβ clearance by the immune response, inadequate clearance of Aβ and amplified chronic 
inflammation by CR1 polymorphisms can contribute to AD pathogenesis130.  
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 Aims of the Thesis 
 
Both CLU and CR1 are two of the most common genes from Alzgene database.  These genes 
comprise risk alleles polymorphisms involved in AD development and pathogenesis, but limited 
evidences are known about the molecular mechanisms involved.  
CLU encodes for the protein clusterin, which is highly expressed in the brains of individuals 
with AD. It can be related to Aβ aggregation, and complement response activation. In fact, in 
individuals with MCI and AD, elevated plasma clusterin is correlated with a more rapid cognitive 
decline. On the other hand, CR1 is a complement receptor present in the cerebral cortex. Emerging 
evidence supports the notion that the complement cascade is involved in neurodegeneration 
process prompted by astrocyte-mediated opsonisation by CR1. Thus, CLU and CR1 have emerged 
as very interesting targets for AD. 
 The aim of this thesis was to address both inflammation-related gene variants in a dementia 
subpopulation group from a primary care-based cohort previously established by the Neuroscience 
and Signalling group. Hence the specific aims of this thesis were to:  
- Perform a literature survey and a bioinformatic analysis on AD inflammation related-
genes; 
- Amplify the polymorphic regions rs11136000 and rs3818361 of CLU and CR1 genes 
respectively, from blood samples of the study group; 
- Determine the genotype and the allelic frequency of the polymorphic regions 
rs11136000 and rs3818361 of CLU and CR1 in the study group; 
- Correlate genotypic and allelic frequencies with dementia. 
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 Materials and Methods 
 Bioinformatics analyses 
 Literature survey on AD risk-related genes and construction of a 
protein-protein interaction network 
The genes identified for this study were collected from a literature survey of review articles 
published between 1/1/2015 to 31/12/2015 at PubMed database131 (using the key words 
Alzheimer’s disease and risk genes, article types), that complemented the data available on AD risk 
related genes. Only the interactions that were curated in Homo sapiens have been included.  
The genes were identified by their own ID: gene symbol (www.genecards.org/)132 and 
UniProtKB identifier (www.uniprot.org/)133. The gene symbol identifier of the collected proteins 
was loaded into STRING database (http://string-db.org)134 to generate a protein-protein interaction 
network. The network was generated using data from “Gene Ontology (GO) Biological Processes”, 
“GO Molecular Functions” and “GO Cellular Components” as a network enrichment method.  
Markov Cluster algorithm (MCL) was also applied in order to calculate the powers of the associated 
adjacency of this network. 
 Gene ontology analysis 
The analysis (adjusted P-value < 0.05) was carried out using STRING database according to 
GO annotation. Data regarding CLU and CR1 genes were collected for ‘biological processes’, 
‘molecular functions’ and ‘cellular component’, particularly focusing on GO in which these genes 
were involved. 
 
 Characterization of the study group 
Our pilot study group included a population of 63 individuals from a cross-sectional 
population-based study on a Portuguese population from the Aveiro region: 32 of which were 
individuals with dementia, based on cognitive evaluation tests, herein referred as “Putative AD” 
group and 31 individuals that forms the Controls group. This is part of a project approved by the 
ethics committee for health of the central regional administration in Coimbra (Comissão de Ética 
para a Saúde da ARS Centro, protocol 0128804-04.04.2012), and by the National Committee for 
Data Protection.  
These 63 individuals represent a subgroup of a total of 590 individuals (568 fulfilled the 
inclusion criteria), nominated by primary care-based cohort (pcb-Cohort). Individuals undertook a 
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survey and were submitted to several cognitive evaluations and dementia screening tests during 
an interview, regardless of the clinical diagnosis. Screening tests comprised Clinical Dementia Rate 
(CDR), Mini Mental State Examination (MMSE), Geriatric Depression Scale (GDS), Katz of Activities 
of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL). A subset of individuals that 
were both CDR positive (CDR≥1, that represents a dementia cognitive rate from moderate to 
severe) and MMSE positive, were designated as “Putative AD” group, which in fact included 
individuals clinically diagnosed for AD. The “Putative AD” group came from a dementia risk group 
of 68 individuals based on CDR classification (Martins et al. 2016, Dementia geriatric cognitive 
disorder, in press), that were also MMSE positive. Controls and “Putative AD” individuals were age 
and sex matched. All participants provided written informed consent for the study. The age and 
gender variables are shown on Table 2. 
 
 Table 2. Representation of the gender and age variables between the “Putative AD” group and the 
Controls group.  
 GENDER  AGE  MEAN AGE 
N % INTERVAL N % 
CONTROLS MALE 76 
10 32% 50-64  3 30 
65-74 1 10 
≥75 6 60 
FEMALE 
21 68% 50-64   2 10 
65-74 4 19 
≥75 1
5 
71 
“PUTATIVE AD” MALE 77 
10 31% 50-64  2 20 
65-74 2 20 
≥75 6 60 
FEMALE 
22 69% 50-64  2 9 
65-74 4 18 
≥75 1
6 
73 
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According to the gender variable, the entire study group was mainly represented by female 
individuals (69% for “Putative AD” group and 68% for the Controls group, against 31% and 32% for 
males from the “Putative AD” group and Controls group, respectively). A large portion of the 
samples were from female individuals over 75 years old for both “Putative AD” and for Controls 
groups, comparative to male individuals.  There were no significant differences regarding the mean 
ages for both analysed groups. 
 
 PCR analyses 
  
Blood samples were collected in EDTA-tubes according to standard procedures and were 
promptly aliquoted and frozen at -80°C, upon arrival in the laboratory. 
 
  
PCR technique is a scientific tool used to replicate DNA from a template, generating 
numerous copies of a specific sequence. This technique was used to amplify a specific portion of 
CLU and CR1 polymorphic regions, respectively rs11136000 (with 685bp) and rs3818361 (with 
664bp) from each patient. For the PCR reaction, Phusion Blood Direct PCR Master Mix 
(ThermoFisher Scientific, USA) was employed according to the manufacturer’s instructions. 1µl of 
whole blood was used in the amplification of each gene and no previous gDNA extraction was 
required. 
Primers were designed as previously described169 and tested for uniqueness using the NCBI 
BLAST W search engine (Table 3).   
 
Table 3: Sequence of the primers and the concentration used for the genotyping of the CLU and CR1 
polymorphism135. 
Gene SNP ID Primer 
name 
Sequence (5’-3’) Concentration 
of primer in 
AS-PCR (μM) 
CLU rs11136000 CLU-Fw 
CLU-Rv 
CCTGGCTTAAAGAATCCACTCATC 
CAGGGGATTCCTTTGAGATAGAGT 
0.1μM 
0.1μM 
CR1 rs3818361 CR1-Fw 
CR1-Rv 
TTCAACTACTGGTTATGGAGCA 
CACTCACCCTTCATCGCAAA 
0.1μM 
0.1μM 
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PCR technique was performed in a final volume of 20 µL, per gene reaction. The PCR round 
comprised 10 µL of 2XPhusion Blood II DNA Polymerase Master Mix (ThermoFisher Scientific, USA), 
1μL of primer forward (Fw) (Eurogentec, Belgium) and 1µL of primer reverse (Rv) (Eurogentec, 
Belgium) of each corresponding gene, 1 μL of whole blood and 7 μL of ultrapure DNase/RNase-free 
distilled H2O (ThermoFisher Scientific, USA).  
The PCR program included an initial denaturation step at 98°C for 5min, followed by 35 
cycles of amplification at 94°C for 1min, 63°C for 30sec and 72°C for 46sec. The final extension was 
performed at 72°C for 5min. 
Following amplification, the PCR products were centrifuged at 1000×g during 1 to 3 min to 
sediment all blood residues and DNA samples were precipitated as described below. 
 
  
1/10 of sodium acetate (pH 3M, pH 5.2), followed by 2.5 volumes of 100% Ethanol were 
added to the solution, which was then mixed and placed at -20°C overnight. Afterwards, the tubes 
were centrifuged at 14000rpm for 20 min at 4⁰C. The supernatant was discarded and 100 μL of 
Ethanol 70% was added to the remaining pellet. The tubes were placed at -20°C for 20 min, and 
later on centrifuged at 14000rpm during 5 min. The supernatant was discarded and the DNA pellet 
was dried out completely at 37°C. Finally, 13 μL of ultrapure DNase/RNase-free distilled H2O was 
added to each tube in order to dissolve the pellet. The purified DNA fragments were stored at -20°C 
for long term storage and/or 4°C for short term storage. 
In order to verify the successful precipitation of the DNA fragments, 2 µL of each sample 
were analysed by agarose gel electrophoresis. DNA was precipitated from 10 µL of the previous 
amplified PCR product. 
 
  
Agarose gel electrophoresis is a technique used for separation of DNA fragments.  As DNA 
is a negatively charged molecule, it migrates from cathode to anode by the porous matrix of 
agarose, via electric field. The separation process occurs according to the fragment size, leading to 
a faster migration by the shorter molecules. The percentage of the agarose gel depends on the DNA 
band size that we intend to examine.  
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Subsequently to the precipitation of the DNA products, conventional electrophoresis was 
executed at 100V for 35 min in 1XTris-acetate-EDTA buffer on 1.5% agarose gel stained with 4 µL 
of GreenSafe Premium® (Nzytech, Portugal)/100ml of agarose (Nzytech, Portugal) solution. From 
the PCR products 2 µL was used to run on the gel. Loading buffer (LB) was added in a ratio of 1:6 to 
increase sample density. The 1Kb Plus DNA Ladder (ThermoFisher Scientific, USA) was used as a 
molecular weight marker. The purified DNA fragments were visualized under ultraviolet (UV) light 
and further analysed with ImageLab 5.2.1 (Bio-Rad Laboratories, Inc., USA) software. 
After DNA precipitation, 10 ml of the product was analyzed by Sanger Sequencing, using the 
previous primers to allow CLU and CR1 polymorphisms detection.  
 
 Sequencing analysis 
Sanger sequencing technique uses a DNA polymerase that copy single-stranded DNA 
templates by assembling nucleotides to a growing chain (extension product). This process occurs in 
the 5' -> 3' direction. At the 3' end of a primer starts the chain elongation, being the place were an 
oligonucleotide anneals to the template. The product extension occurs by additional 
deoxynucleotides incorporation by complementary to the template. The extension product grows 
by the formation of a phosphodiester bridge among the 3'-hydroxyl group on the primer and the 
5'-phosphate group of the incoming deoxynucleotide, which enables the development of the 
extension product.  
Further, DNA polymerases can also add analogues of nucleotide bases, as the dideoxy method 
of DNA sequencing that uses 2',3'-dideoxynucleotides as substrates. When dideoxynucleotides are 
combined at the 3' end of the developing chain, chain elongation is completed selectively at A, C, 
G, or T. After the binding of the dideoxynucleotide, the chain is absent of a 3'-hydroxyl group 
therefore further elongation of the chain is prevented. 
The sequencing results were analysed with BioEdit (Ibis Biosciences, Carlsbad USA) software.  
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 Results  
 Bioinformatics analyses of CLU and CR1 genes in AD pathology 
In the field of AD, there are several GWAS emphasising novel potential susceptibility loci, 
beyond the well-established APOE4 association with disease. The markers on a GWAS array 
comprise selected gene polymorphic variants based on their aptitude to cover common variation 
in the human genome. An increasing amount of other GWAS risk genes for AD involved in 
inﬂammation have been discovered, among those are CLU and CR1. 
To better understand the involvement of these genes in AD, a search for the available AD 
related-genes and their interacting proteins was performed in databases and in the literature. The 
retrieved information was further analysed by raising a protein-protein interaction (PPI) network, 
and by performing a Gene Ontology (GO) (adjusted P-value<0.05) term enrichment, a pathway 
analysis for gene characterization. Particular emphasis was additionally given to inflammation and 
immune response related-genes, as CLU and CR1.  
 
 Interaction network of AD risk-related genes 
During the literature search, information regarding several genes involved in AD 
pathogenesis but also associated with inflammation and immune response were collected. To 
identify the common inflammation and immune response interactors of AD risk-related genes, 
human protein ID were collected from several reports from the public database PubMed. 
Furthermore, in order to evaluate the AD related genes interaction network, human protein ID’s of 
those genes were introduced in STRING database, which raised a PPI network, where only curated 
interactions have been considered. 
A total of 32 genes were identified as AD interacting genes, among which 14 genes were 
associated with immune response. As expected, both CLU and CR1 were identified within the 14 
gene list. The full list of AD related-genes and its association with inflammation and immune 
response pathways is presented in Table S1 (Appendix 1).  
A network was generated using “Biological process based” as the network weighting 
method. A total of 32 proteins (UniProtKB identifier corresponding to the above mentioned genes) 
were used as input on STRING. The extracted network consists of 32 protein nodes and 68 predicted 
associations between these proteins (Figure 10).  
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The originated network showed multiple proteins and clusters organized by different sizes 
and colours. Such clustering indicates that the proteins are at least partially biologically connected, 
as a group. Coloured lines between the proteins indicated the various types of interaction evidence. 
Each interaction between nodes was created and represented by different colours, being separated 
by boundaries with no flow. This network was the result of clustering proteins by common features 
(high-flow regions). The obtained network showed 5 separated clusters highlighted by different 
colours (bue cluster, yellow cluster, red cluster, green cluster and brown cluster), that were 
obtained according to the MCL clustering (MCL=3) applied algorithm analysis.  (Figure 10). 
There are also several disconnected nodes in this network including CELF1, CASS4, PLD3, 
TREM2, MEF2C and NYAP1, which mean that these nodes have no proven direct association to date. 
Still, these proteins are represented in the network by a respective colour, which links these nodes 
to specific clusters within this network. 
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The highest edge confidence cluster in the network (blue cluster) was associated with the 
most numbers of nodes, including DSG2, PSEN1, PSEN2, ADAM10, MADD, SORL1, APOE, APP and 
CLU. The disconnected node CELF1 is likewise associated with this cluster. As expected, this cluster 
includes the most well-known genes contributing to AD pathogenesis, such as APP, PSEN1, PSEN2 
and APOE. CLU, a protein associated with Aβ clearance, was strongly linked to the proteins APP, 
APOE and PSEN1.  
Figure 10: Interaction network of AD risk related-genes. This protein interaction network consists of 32 protein nodes 
and 68 protein interactions analysed by String database. The network nodes are proteins and the edges are represented 
by predicted confidence associations represented by blue line thickness or blue dots, as an indication of the available 
data support between the nodes. Five separated clusters were obtained using the clustering algorithm MCL (MCL=3).  
(Low edge confidence (dots): 0.150; Medium edge confidence: 0.400; High edge confidence: 0.700; Highest edge 
confidence (darker blue line: 0.900).  
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CR1 was associated with the cluster that included the nodes RIN3, PICALM, BIN1, ABCA7, 
MS4A6A and CD33 (yellow cluster), which represent common proteins associated with LOAD. CR1, 
a protein related to immune response and also to Aβ clearance was directly linked to BIN1, ABCA7, 
MS4A6A, PICALM and CD33 by medium confidence edges. It was also connected to CLU by a low 
confidence edge.  
HLA-DRB1 and HLA-DRB5 nodes, two members of the major histocompatibility complex, 
were the only proteins that represented the green cluster in this network. Despite being 
disconnected nodes, CASS4, PDL3 and TREM2 (represented by green coloured nodes) are also 
related to this cluster. 
The nodes EPHA1, CD2AP, INPP5D, PTK2B and FERMT2 were included in the red cluster, as 
the disconnected NYAP1 node. This cluster is centrally represented by CD2AP, which is linked to 
EPHA1 by high edge confidence association, and to INPP5D, PTK2B and FERMT2 by medium edge 
confidence. Still, SLC24A4, ZCWPW1 and NME8 were the only members of the brown cluster, being 
all linked by medium edge confidence.  
 
 GO analysis of CLU and CR1 within the AD risk-related genes network 
CLU and CR1 AD risk-genes identified in the present study were analyzed by STRING 
database according to GO annotation by grouping them into 3 categories: biological processes, 
molecular functions and cellular components. The statistical method using the Bonferroni 
correction was applied and only GO terms with a p-value < 0.05 were considered. 
Particular emphasis was given to CLU and CR1 and to the inflammation related processes 
in which these genes were involved. The results obtained from the network regarding the biological 
process revealed 15 GO terms, where CLU and CR1 were found. All of these GO terms were also 
associated features within inflammation and immune response processes (Table 4).  
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Table 4: GO terms regarding biological processes associating CLU and CR1 within the AD risk-related 
genes network. “Count in gene set” indicates the total number of counted proteins that were categorized 
from the network. p-value < 0,05. 
 
 
 
BIOLOGICAL PROCESSES 
GO term Count in gene set Gene ID p-value 
Adaptive immune 
response based on 
somatic recombination 
of immune receptors 
built from 
immunoglobulin 
superfamily domains 
5 INPP5D, HLA-DRB1, 
MEF2C, CR1, CLU  
3.159e-4 
Positive regulation of 
immune system process 
9 ADAM10, PSEN1, CLU, 
CR1, HLA-DRB1, HLA-
DRB5, MEF2C, TREM2, 
PTK2B 
4.459e-4 
Humoral immune 
response 
5 CLU, CR1, HLA-DRB1, 
MEF2C, TREM2 
4.499e-4 
Activation of immune 
response 
7 CLU, CR1, PSEN1, HLA-
DRB1, HLA-DRB5, 
INPP5D, MEF2C 
5.890e-4 
Immune response-
activating cell surface 
receptor signalling 
pathway 
6 CR1, PSEN1, HLA-DRB1, 
HLA-DRB5, INPP5D, 
MEF2C 
5.890e-4 
Immunoglobulin 
mediated immune 
response 
4 CLU, CR1, INPP5D, HLA-
DRB1 
6.740e-4 
Immune response 10 APP, CLU, PSEN1, CR1, 
MEF2C, TREM2, HLA-
DRB1, HLA-DRB5, 
INPP5D, PT2KB 
1.250e-3 
Humoral immune 
response mediated by 
circulating 
immunoglobulin 
3 CLU, CR1, HLA-DRB1 2.799e-3 
Immune effector 
process 
6 CLU, CR1, PSEN1, HLA-
DRB1, INPP5D, PT2KB 
3.650e-3 
Innate immune 
response 
8 APP, CLU, CR1, PT2KB, 
HLA-DRB1, HLA-DRB5, 
MEF2C, TREM2 
4.040e-3 
Immune system process 11 APP, CLU, CR1, PSEN1, 
PT2KB, HLA-DRB1, HLA-
DRB5, MEF2C, TREM2, 
PICALM, ADAM10 
4.579e-3 
Leukocyte activation 5 ADAM10, PSEN1, CLU, 
MEF2C, PT2KB 
1.679e-2 
Myeloid leukocyte 
activation 
3 ADAM10, CLU, PSEN1 2.380e-2 
Regulation of immune 
response 
6 PSEN1, CLU, CR1, 
MEF2C, HLA-DRB1, HLA-
DRB5 
4.050e-2 
Complement activation, 
classical pathway 
2 CLU, CR1 4.700e-2 
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Both CLU and CR1 were associated with the following GO terms: Adaptive immune response 
based on somatic recombination of immune receptors built from immunoglobulin superfamily 
domains (p=3.159e-4), Positive regulation of immune system process (p=4.459e-4), Humoral 
immune response (p=4.499e-4), Activation of immune response (p=5.890e-4), Immunoglobulin 
mediated immune response (p=6.740e-4), Immune response (p=1.250e-3), Humoral immune 
response mediated by circulating immunoglobulin (p=2.799e-3), Immune effector process 
(p=3.650e-3), Innate immune response (p=4.040e-3), Immune system process (p=4.579e-3), 
Regulation of immune response (p=4.050e-2) and Complement activation, classical pathway 
(p=4.700e-2). The GO term Immune response-activating cell surface receptor signaling pathway 
(P=5.890e-4) was found for CR1, whereas CLU was observed with Leukocyte activation (p=1.679e-
2) and Myeloid leukocyte activation (p=2.380e-2). The GO term Complement activation, classical 
pathway (p=4.700e-2) was found only for the two proteins, CLU and CR1 as expected. 
The results obtained from the network regarding the molecular function revealed 1 GO 
term, where CLU and CR1 were found (Table 5). This GO term was associated with protein binding 
processes (p=4.419e-3). 
 
MOLECULAR FUNCTION  
GO term Count in gene set Gene ID p-value 
Protein binding 20 APP, RIN3, BIN1, CR1, 
CLU, CD2AP, EPHA1, 
PICALM, APOE, SORL1, 
PSEN1, PSEN2, 
ADAM10, PTK2B, 
MADD, DSG2, HLA-
DRB1, TREM2, MEF2C, 
NME8 
4.419e-3 
 
The results obtained from the network regarding the cellular component revealed 5 GO 
terms, where CLU and CR1 were presented (Table 6).  
 
 
 
 
Table 5: GO terms regarding molecular function associating CLU and CR1 within the AD risk-related genes 
network. “Count in gene set” indicates the total number of counted proteins that were categorized from 
the network. p-value < 0,05. 
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Table 6: GO terms regarding cellular component associating CLU and CR1 within the AD risk-related genes 
network. “Count in gene set” indicates the total number of counted proteins that were categorized from the 
network. p-value < 0,05. 
. p-value < 0,05. 
 
CELLULAR COMPONENT  
GO term Count in gene set Gene ID P-value 
Neurofibrillary tangle 2 CLU, PICALM 2.490e-3 
Plasma lipoprotein 
particle 
3 CLU, APOE, SORL1 2.969e-3 
Cell surface 9 APP, ADAM10, PSEN1, 
ABCA7, CR1, CD33, 
DGS2, FERMT2, HLA-
DRB1 
2.200e-4 
Intracellular 22 RIN3, CELF1, BIN1, CLU, 
PLD3, HLA-DRB1, HLA-
DRB5, ABCA7, PICALM, 
SORL1, APP, APOE, 
ADAM10, TREM2, 
MEF2C, INPP5D, PTK2B, 
NYAP1, MADD, CASS4, 
SLC24A4, NME8 
8.549e-1 
Plasma membrane part 16 ADAM10, APP, PSEN1, 
SORL1, BIN1, PICALM, 
EPHA1, ABCA7, CR1, 
HLA-DRB1, HLA-DRB5, 
CD33, SLC24A4, DSG2, 
FERMT2, PTK2B 
2.010e-5 
 
 
The GO terms Neurofibrillary tangle (p=2.490e-3), Plasma lipoprotein particle (p=2.969e-3) 
and Intracellular (p=8.549e-1) were associated with CLU, while CR1 was related to Cell surface 
(p=2.200e-4) and Plasma membrane part (p=2.010e-5).  
 
 CLU polymorphic region rs11136000 and CR1 polymorphic region 
rs3818361 amplification by PCR  
Another aim of this thesis was to evaluate the frequency of CLU and CR1 polymorphic 
regions rs11136000 and rs3818361 respectively in Controls and dementia individuals (here referred 
as “Putative AD” individuals) from a population-based subgroup of individuals, the pcb-cohort. The 
final aim was to address the potential risk association between these susceptibility SNPs and the 
disease risk group. 
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In order to perform CLU and CR1 genotyping, the SNPs were amplified by PCR. The results 
were subsequently visualized in 1.5% agarose gels. The expected fragment of 685bp for CLU SNP 
(Figure 11) and the expected fragment of 664bp for CR1 SNP (Figure 12) were obtained for all cases.  
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Figure 11: Representative gel of a set of “Putative AD” and Controls individuals. CLU SNP amplified by 
PCR technique. The expected product band has 685bp and was visualized in 1.5% agarose gel. 
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Figure 12: Representative gel of a set of “Putative AD” and Controls individuals. CR1 SNP amplified by 
PCR technique. The expected product band has 664bp and was visualized in 1.5% agarose gel.  
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 Associating the CLU and CR1 SNP genotype with AD 
Following PCR, all DNA samples were purified and successively evaluated by Sanger 
Sequencing.   Representative sequencing patterns of each SNP for CLU and CR1 genes are presented 
in Figure 13 and Figure 14, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
CT genotype, Heterozygous risk carrier 
B 
C 
Figure 13: Examples of Sanger-sequencing results for CLU rs11136000 SNP from the studied 
individuals. A - CT genotype, Heterozygous risk carrier. B – CC genotype, Homozygous risk-
carrier. C - TT genotype, Homozygous non-risk carrier. 
TT genotype, Homozygous non-risk carrier 
CC genotype, Homozygous risk carrier 
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A 
AG genotype, Heterozygous risk carrier 
B 
C 
Figure 14: Examples of Sanger-sequencing results for CR1 rs3818361 SNP from the studied 
individuals. The gene was sequenced with the primer reverse, which explains the difference 
between the complementary nucleotide on the sequence and the indicated genotype nucleotide. 
A - TC that corresponds to AG genotype, Heterozygous risk carrier. B - TT that corresponds to 
genotype AA, Homozygous risk-carrier. C – CC that corresponds to GG genotype, Homozygous non-
risk carrier. 
GG genotype, Homozygous non-risk carrier 
AA genotype, Homozygous risk carrier 
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 Determination of CLU and CR1 SNPs genotypic frequencies  
 CLU rs11136000 SNP genotypic frequencies  
 After sequencing results analysis from CLU rs11136000 SNP, it was possible to identify in 
the “Putative AD” group:  14 homozygous risk-carriers with CC genotype, 13 heterozygous risk 
carriers with CT genotype and 5 homozygous non-risk carriers with TT genotype. From the Controls 
group sequencing analysis, it was identified 14 homozygous risk-carriers with CC genotype, 11 
heterozygous risk carriers with CT genotype and 7 homozygous non-risk carriers with TT genotype. 
The Entire study group showed a frequency of 63 individuals. All data is represented as a percentage 
for each group in Figure 15. 
 
 
 
 
 
Figure 15: Analysis of the genotyping frequencies for CLU rs11136000 SNP in “Putative 
AD”, Controls and Entire study group. CT - Heterozygous risk carriers with CT genotype; CC 
- Homozygous risk-carriers with CC genotype; TT - Homozygous non-risk carriers with TT 
genotype. 
 
40%
44%
16%
"PUTATIVE AD"
CT CC TT
N = 32
34%
44%
22%
CONTROLS
CT CC TT
N = 31
38%
43%
19%
ENTIRE STUDY GROUP
CT CC TT
N = 63
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According to the data obtained, the most frequent group in “Putative AD” are homozygous-
risk carriers being represented by CC genotype (44%), followed by the heterozygous risk carriers 
with CT genotype (40%). Additionally, the less frequent group of “Putative AD” group are 
homozygous non-risk carriers with TT genotype (16%). The most frequent group in Controls are 
likewise homozygous risk-carriers being represented by CC genotype (44%), followed by the 
heterozygous risk carriers with CT genotype (34%). Furthermore, the less frequent group of 
Controls are homozygous non-risk carriers with TT genotype (22%), although at a higher percentage 
than in “Putative AD” group. Although no percentage differences were obtained for the 
homozygous risk-carries among groups, a slight increase was obtained for the heterozygous risk-
carriers in AD group. 
 Assuming all the sequencing information of the entire study group (Controls and “Putative 
AD”), the CLU genotyping frequencies did not change much: 27 homozygous risk carriers being 
represented by CC genotype (43%), 24 heterozygous risk carriers with CT genotype (38%) and 12 
homozygous non-risk carriers with TT genotype (19%) (Figure 15). In fact, considering all 63 
analysed individuals in total, the order of the genotypes frequencies was: CC > CT > TT, the same 
frequency observed for the individual groups. 
 
 CR1 rs3818361 SNP genotypic frequencies 
Regarding the sequencing results for the CR1 rs3818361 SNP, in the “Putative AD” group it 
was identified: 2 homozygous risk carriers with AA genotype, 4 heterozygous risk carriers with AG 
genotype and 26 homozygous non-risk carriers with GG genotype. For the Controls group: no 
homozygous risk-carriers with AA genotype, 6 heterozygous risk carriers with AG genotype and 26 
homozygous non-risk carriers with GG genotype. A 6% increase in homozygous risk-carriers were 
found in “Putative AD” group.  In total, it was possible to identify from the sequencing analysis of 
the Entire study group (“Putative AD” and Controls) that 10 individuals were heterozygous risk 
carriers with AG genotype, 51 individuals were homozygous non-risk carriers with GG genotype and 
2 individuals were homozygous risk carriers with AA genotype. Data is represented in percentages 
in Figure 16. 
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According to the data, the most frequent group in “Putative AD” group are homozygous non-
risk carriers with GG genotype (81%), followed by the heterozygous risk carriers with AG genotype 
(13%). Additionally, the less frequent group of “Putative AD” individuals are homozygous risk 
carriers with AA genotype (6%). For the Controls group, the most frequent are homozygous non-
risk carriers with GG genotype (81%), and the less frequent are heterozygous risk carriers with AG 
genotype (19%). Of note, no homozygous risk carriers with AA genotype were present in the 
Controls group.  
 
 
Figure 16: Analysis of the genotyping frequencies for CR1 rs3818361 SNP in “Putative AD”, 
Controls and Entire study group. AG - Heterozygous risk carriers with AG genotype; AA - 
Homozygous risk carriers with AA genotype; GG - Homozygous non-risk carriers with GG 
genotype. 
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DCM/UA 2016 
 
Testing a dementia risk group for polymorphisms in inflammation-related 
genes   44 
  
Assuming the sequencing information from both “Putative AD” patients and Controls, this 
study identified in the Entire study group 2 homozygous risk carriers represented by AA genotype 
(3%), 10 heterozygous risk carriers with AG genotype (16%) and 51 homozygous non-risk carriers 
with GG genotype (81%) (Figure 16). Considering all individuals analysed, the frequency of the 
genotypes was: GG > AG > AA. 
 
 Evaluation of CLU rs11136000 SNP and CR1 rs3818361 SNP allelic 
frequencies 
 CLU rs11136000 SNP allelic frequencies 
The most common allelic frequencies of CLU rs11136000 SNP in “Putative AD” group was 
the risk allele (C-allele), with 41 alleles. The T-allele was the less frequent (23 from a total of 64 
alleles). By contrast, for the Controls group, out of 62 alleles, the T-allele was the most frequent (37 
alleles) and the C-allele was much less frequent than in “Putative AD” group (only in 25 alleles). By 
analysing CLU rs11136000 SNP sequences in both groups, it was possible to recognize that the C-
allele was the most frequent with 66 alleles from a total of 126. The T-allele was the less frequent, 
since it was only present in 60 alleles from a total of 126 alleles. Data is represented in percentages 
in the following Figure 17. 
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In fact, by calculating the allelic frequencies for the “Putative AD” group, the T-allele 
represents a frequency of 36%, while the C-allele represents a higher frequency of 64%. Relatively 
to the Control group, the T-allele exhibited a frequency of 60% and the C-allele of only 40%. By 
analysing all individuals of both groups, the C-allele is slightly more frequent than the T-allele of 
52% versus 48%, respectively. 
 
 
36%
64%
"PUTATIVE AD"
T-Allele C-Allele
N = 64
60%
40%
CONTROLS
T-Allele C-Allele
N = 62
48%
52%
ENTIRE STUDY GROUP
T-Allele C-Allele
N = 126
Figure 17: Sequencing results for CLU rs11136000 SNP allelic frequencies from all the studied 
groups. T-allele, non-risk allele; C-allele, risk allele. 
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 CR1 rs3818361 SNP allelic frequencies 
According to the allelic frequencies for CR1 rs3818361 SNP, the most frequent allele in the 
“Putative AD” group was the G-allele, with 56 alleles. Moreover, the A-allele was the less frequent 
(8 from a total of 64 alleles). Similarly, for the Controls individuals, the G-allele was the most 
frequent (56 alleles out of 64), and the A-allele was only 6 alleles. For the CR1 rs3818361 SNP in the 
Entire study group, the G-allele was the most frequent with 112 alleles from a total of 126. Likewise, 
the A-allele was the less frequent, since it was 14 alleles from a total of 126 alleles. All data is 
represented as a percentage for each group in Figure 18. 
 
  
   
 
 
 
 
 
 
Figure 18: Sequencing results for CR1 rs3818361 SNP allelic frequencies from all the studied 
groups. A-allele, risk allele; G-allele, non-risk allele. 
 
12%
88%
"PUTATIVE AD"
A-Allele G-Allele
N = 64
10%
90%
CONTROLS
A-Allele G-Allele
N = 62
11%
89%
ENTIRE STUDY GROUP
A-Allele G-Allele
N = 126
DCM/UA 2016 
 
Testing a dementia risk group for polymorphisms in inflammation-related 
genes   47 
  
The allelic frequencies of CR1 rs3818361 SNP in “Putative AD” group were higher for the G-
allele (88%) than for the A-allele (was only 12%). Similarly, results were obtained for the Controls 
group were the A-allele was associated with a lower frequency (10%) and the G-allele with higher 
frequency (90%). The allelic frequencies analysed of the entire study group did not change much 
when compared with the individual group frequencies already described. The G-allele showed a 
frequency of 89% and the A-allele lower frequency of 11%. 
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 Discussion 
The incidence and prevalence of AD increases with age and amplifies exponentially 
every five years after the sixth decade of life. Demographic aging is a reality worldwide, being 
expectable that the sum of AD cases will escalate in the near future24. 
Considering the restricted efficacy of potential interventions and diagnostics tools for 
the current dementia cases, studies have centred on the understanding of the molecular basics 
of the disease, to promote the development of premature diagnostic tools and disease-
modifying effective therapeutic approaches. Understanding the interface among 
environmental and genetic aspects that control risk factors and outcomes of neurologic 
disease can deliver valuable information on dealing with this devastating disorder16. 
In this perspective, the work here presented aimed to study AD-related risk genes, in 
particular the CLU rs11136000 and CR1 rs3818361 risk variants, which were analysed in a pilot 
study group of 63 individuals. 
 
 AD risk-related genes network 
The first step of this work was to perform a bioinformatics analysis of the AD associated 
risk-genes.  
A powerful approach for inquiring the biological relationships of a protein of interest 
is to analyse the protein-protein interactions networks. In our network, 5 separated clusters 
were obtained, exhibiting proteins that are already known to be associated with AD 
pathogenesis.  
One cluster included the APP node and is associated with Presenilin genes (PSEN1 and 
PSEN2), APOE, SORL1, ADAM10 and CLU, linked by highest edge confidence (blue cluster). 
These genes centrally connected to APP node represent key players in APP processing and Aβ 
clearance in EOAD and LOAD, in agreement with literature data. CLU is also linked to APOE 
node by high edge confidence, which may be associated to the fact that both genes are 
inflammatory-related apolipoproteins involved in lipid metabolism. CELF1 is also related with 
this cluster. This gene may mediate tau toxicity and neuronal development24.  
Another cluster included BIN1, PICALM and RIN3 (yellow cluster), all strongly 
associated by highest edge confidence. This may indicate that all these genes share common 
pathway features. In fact, all these genes associate with synapse function and neural 
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development24. CR1 is also present in this cluster and it was associated by medium edge 
confidence to CD33, ABCA7, PICALM and MS4A6A, suggesting that these genes might at some 
point interplay in synapse function and immune response processes24.  
The CD2AP is a central node (red cluster), which may indicate that this gene has an 
important function associating EPHA1, INPP5D, PTK2B and FERMT2 to synapse function and 
endocytosis processes24. 
HLA-DRB1 and HLA-DRB5 were also linked in this network (green cluster).  Both genes 
are HLA class II molecules and may act as an antigen-presenting molecule by regulating the 
specific immune response and innate immune response, potentially contributing to the 
alteration of these processes in AD24.  
NME8, ZCWPW1 and SLC24A4 were all associated by medium edge confidence (brown 
cluster). To date very little is known to date about these genes, but they have been associated 
to LOAD and may be important players in neural development24.  
 
 GO analysis of CLU and CR1 within the AD risk-related genes network 
Next, we identified functional terms for the studied genes, CLU and CR1, within the AD 
risk-related genes network by using Gene Ontology (GO) analysis. In the obtained network, it 
was possible to identify 21 significantly enriched terms: 15 biological process, 1 predominant 
molecular function and 5 cellular components in total. Some of these are consistent with the 
current knowledge of the biological functions and compartments linked to these genes and 
implicated in AD processes, such as neuroinflammation and the immune system 
responses24,122.  
For instance, it was demonstrated that CLU and CR1 are associated with several 
inflammation and immune response biological processes within AD risk-related genes 
network. By the network results, CR1 was associated with immune response-activating cell 
surface receptor signaling pathway, while CLU was linked to leukocyte activation and myeloid 
leukocyte activation. Both genes were common players in complement activation, classical 
pathway and are also involved with Aβ clearance24. In AD, Aβ deposition induces complement 
activation and activates microglial cells, which ultimately stimulates the brain inflammatory 
response25,98. 
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Regarding the molecular function, both genes were associated with protein binding 
features. For instance, CLU actions as an extracellular chaperone, were shown to prevent the 
aggregation of non-active proteins117. CR1 has been described as a mediator in cellular binding 
of particles and immune complexes that activated the complement111. 
About the cellular component data, CLU may be a part of the neurofibrillary tangle in 
association with PICALM and a plasma lipoprotein particle in association with SORL1. It could 
also be related to other intracellular components. On the other hand, CR1 may be associated 
with cell surface and plasma membrane part components. These results are in line with 
previous findings111, which revealed that the recognition of immune-complexes by the 
complement protein might occur by collagen-like receptor binding domains of C1q or mannose 
binding proteins, which after triggered, will activate a cascade of several proteins from the 
complement pathway. 
 
 CLU rs11136000 profile  
Neuroinflammation is recognized as a downstream event of the amyloid cascade 
hypothesis. In fact, Aβ within the CNS promotes microglia activation and instigates a pro-
inflammatory cascade that ultimately contributes to the release of inflammatory and 
neurotoxic substances, such as cytokines, chemokines, reactive oxygen and nitrogen species, 
and various proteolytic enzymes, that lead to neuroinflammation and degenerative outcomes 
in neurons. This data supports the need to discover and analyse new risk variants of genes 
encoding immune system molecules, such as CLU and CR1, that have been shown to be 
elevated in tissues and body fluids of individuals with AD or prodromal forms of this disease. 
Furthermore, GWAS have shown that both genes may be linked to AD pathogenesis and 
increased risk26,27. 
CLU is a widely expressed multifunctional glycoprotein, present in amyloid plaques and 
significant elevated in AD patients. It is one of the primary chaperones for removal of Aβ from 
the brain, by modulating astrocyte and microglia activation114. According to several studies, 
CLU can likewise interact with Aβ peptides, playing a central function in Aβ aggregation, 
toxicity and clearance as a potential controller of inflammation in AD pathogenesis.  
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In our study, the genotype frequencies for CLU were similar for both groups: CC > CT > 
TT, with the respective percentages being: 43%, 38% and 19%, when we look at the entire 
analysed group. These results are in agreement with the genotype frequencies obtained in an 
Asian CLU rs11136000 cross-sectional population reports from ALZgene Database136.   
According to our data for the Entire study group, 43% of tested individuals expressed 
the risk genotype (CC Homozygous genotype) while 19% presented the protective genotype 
(TT Homozygous genotype). Previous studies showed that the former individuals may have 
increased task-related activation26,102, which could reflect alteration in brain function, while 
nonrisk genotype individuals exhibited less brain activation potentially by using a more 
proficient and resourceful approach. Further, despite the fact that no differences were 
obtained for the homozygous risk carriers frequencies between “Putative AD” and Controls 
groups, a slight increase in heterozygous risk carriers was observed in the former group. 
On the other hand, according to our allelic frequencies results, differences arise 
between the “Putative AD” group and the Controls group. In fact, the “Putative AD” individuals 
exhibited a greater frequency for the C-risk allele of 64%, comparatively to the Controls group 
(40%). Inversely, the T-non risk-allele had a higher frequency in the Controls group of 60%. 
Data is consistent with previous studies which demonstrated that rs11136000 polymorphic 
region of CLU is associated with increased risk of AD127. Besides this study, others had 
consistently reported that the C-risk allele carriers demonstrated earlier rates of decline in 
memory performance relative to T-non-risk allele carriers. Furthermore, the T-allele of the CLU 
variant rs11136000 is presuming related with low risk to AD development and enhanced 
cognitive performance, while the homozygous expression of the C-allele is accepted as risk 
factor for AD104. Likewise, CLU also yields effects on early, pre-symptomatic stages of disease 
progression by hastening deterioration in memory performance in risk carriers who ultimately 
evolve to MCI/AD. These data implicate CLU in initial stages of AD pathogenesis and supports 
the notion that it may be essential in controlling disease development in carriers of this 
common risk variant. 
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Furthermore, by examining our data from the Entire study group, the C-risk allele 
ultimately expresses a frequency of 52% and the T-non-risk-allele showed a lower frequency 
of only 48%, which is in accordance with the Caucasian CLU rs11136000 cross-sectional 
population reports from ALZgene Database136. Despite the small size of our study group, it was 
possible to sustain the association between CLU rs11136000 C-risk allele carriers and the 
“Putative AD” individuals. 
 
 CR1 rs3818361 profile 
The CR1 gene is located in a genetic cluster of complement activation genes. It is a 
multifunctional protein, which is broadly expressed by the brain defensive cells. Furthermore, 
CR1 inhibits complement activation by diminishing the immune response and limiting adjacent 
tissue impairment. In the brain, it is hypothesized that CR1 could act by reducing inflammation 
levels in AD through clearance of Aβ deposits and by protecting healthy neurons from 
inflammation-mediated damage126. Further, CR1 may act as a brain receptor for Aβ and its 
levels are increased in AD patients24. These observations support the notion that CR1 is 
involved in AD pathogenesis. 
Additional, the rs3818361 polymorphic region of CR1 gene has been associated with 
increased risk of AD in GWAS26. Nonetheless, for the rs3818361 polymorphism, risk carriers (A-
allele) exhibited lower brain amyloid burden relative to non-risk carriers (G-allele), an effect 
that can be influenced by APOE genotype120. The later observation suggests that the clinical 
utility of this variant as disease risk factor may be limited. Hence in our study the relation of 
this CR1 variant with dementia was also addressed. 
Regarding the CR1 rs3818361 polymorphism and considering the Entire study group, 
the genotype frequencies were: GG > AG > AA. These results agree with the genotypic 
frequencies obtained in an European CR1 rs3818361 cross-sectional population study 
(Ensemble Database studies (http://www.ensembl.org/))137.  
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According to our data, 81% of the tested individuals expressed the non-risk GG 
homozygous genotype while 19% expressed the risk AA homozygous genotype and the risk AG 
heterozygous genotype carriers (respectively, 16% and 3%). Although no differences were 
detected between the “Putative AD” group and the Controls group relatively to the 
homozygous non-risk genotype frequencies, the “Putative AD” group exhibited an increased 
frequency of homozygous risk-carriers, consistent with previous reported observations. 
For this genetic variant, similar results were obtained for the allelic frequencies for all 
groups, with the non-risk allele being the most frequent. In fact, on the “Putative AD” group, 
the A-risk allele had the lowest frequency (12%), when compared to the G-non-risk allele. 
Additionally, for the Controls group, the A-allele also displayed a 10% frequency, similarly to 
that observed for the “Putative AD” group. This rs3818361 polymorphic region of CR1 gene 
was previously associated with increased risk of AD. Furthermore, inadequate clearance of Aβ 
and amplified chronic inflammation by CR1 genetic variation appears to be associated with AD 
pathogenesis of AD, with a current report proposing that forms of CR1 with lower clearance 
are associated with higher risk of AD26.  
By examining all individuals from both groups (Entire study group), the G-non-risk-
allele expresses a superior frequency (89%) than the A-risk-allele (11%), which is consistent 
with the European CR1 rs3818361 cross-sectional population report from Ensemble Database 
studies (http://www.ensembl.org/)137. No significant association of CR1 rs3818361 risk-allele 
with “Putative AD” individuals were identified, only 2% difference between groups. This may 
be related with the small number of samples analysed.  
Further analysis with a higher number of individuals may help to confirm if these SNPs 
could actually have an impact on our population or relevance in dementia/”Putative AD” cases. 
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 Conclusions 
 
 Both CLU and CR1 are common interactors in inflammation and immune response 
processes; 
 For CLU polymorphism the percentage of homozygous risk-carriers individuals was the 
same in both groups. Nonetheless, the percentage of heterozygous risk-carriers was 
higher in the “Putative AD” group; 
 Regarding the CLU allelic frequencies of the variant, a higher percentage of individuals 
in the “Putative AD” group exhibited the C-risk allele; 
 For the CR1, an increase in the percentage of homozygous risk carriers in the “Putative 
AD” group was observed comparatively to the Controls group; 
 Allelic frequencies of the CR1 variant did not change much among both groups; 
 For both genetic variants, the genotypic frequencies obtained for the Entire study 
group are in agreement with previous observations; 
 Although some correlations could be identified between these polymorphisms and the 
“Putative AD” group, strong evidences should be supported by additional studies with 
increased number of individuals. 
 
 Future Perspectives 
o Increase the number of samples in the entire group, including the number of 
“Putative AD“ individuals; 
o Analyze and estimate the genotypic frequencies and the allelic frequencies of 
CLU rs11136000 in MCI individuals; 
o Establish correlations analysis with APOEε4 allele, since it is one of the major 
risk factors for LOAD; 
o Perform a plasma analysis of CLU in demented and non-demented older 
individuals, correlate it with the genetic profiles, and ideally with amyloid β-
deposition. 
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Appendix 1 
Table S1. AD risk associated genes (black) and AD inflammation associated genes (grey) provided from GWAS to date24. 
Gene 
(Protein) 
Known function 
Potential 
Effects on 
APP and Tau 
Pathways 
Gene 
Expression 
UniProt 
ID 
APP (Amyloid 
beta (A4) 
precursor 
protein) 
Neurite outgrowth, 
adhesion and 
axonogenesis 
Cleavage 
yields Aβ 
APP 
processing 
- 
P05067 
PSEN1 
(Presenilin-1) 
Component of 
catalytic subunit of 
gammasecretase 
complex. Proteolytic 
cleavage of integral 
membrane proteins Cleaves APP 
APP 
processing  
- 
P49768 
PSEN2 
(Presenilin-2) 
Component of 
catalytic subunit of 
gammasecretase 
complex. Proteolytic 
cleavage of integral 
membrane proteins Cleaves APP 
APP 
processing  
- 
P49810 
APOE 
(Apolipoprot
ein E) 
Mediates binding, 
internalization and 
catabolism of 
lipoproteins Aβ clearance 
Lipid 
metabolism  
- 
P02649 
ADAM 10 
(Disintegrin 
and 
metalloprotei
nase domain-
containing 
protein 10) 
Proteolytic cleavage of 
integral membrane 
proteins Cleaves APP 
APP 
processing 
- 
O14672 
CR1 
(Complement 
receptor type 
1) 
Mediates cellular 
binding of immune 
complexes that 
activate complement Aβ clearance 
Immune 
response 
Increased 
P17927 
BIN1 (Myc 
box-
dependent-
interacting 
protein 1) 
Regulation of 
endocytosis of 
synaptic vesicles 
Mediates tau 
toxicity 
Synapse 
function 
Increased 
O00499 
CD2AP (CD2-
associated 
protein) 
Scaffold molecule 
regulating actin 
cytoskeleton 
Mediates tau 
toxicity 
Synapse 
function & 
Endocytosis 
No change 
Q9Y5K6 
EPHA1 
(Ephrin type-
A receptor 1) 
Brain and neural 
development. 
Angiogenesis, cell 
proliferation, and 
apoptosis N/A 
Immune 
response & 
Neural 
developme
nt 
No change 
P21709 
CLU 
(Clusterin) 
Chaperone. 
Regulation of cell 
proliferation Aβ clearance 
Immune 
response & 
Increased 
P10909 
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Gene 
(Protein) 
Known function 
Potential 
Effects on 
APP and Tau 
Pathways 
Gene 
Expression 
UniProt 
ID 
Lipid 
metabolism 
MS4A6A 
(Membrane-
spanning 4-
domains 
subfamily A 
member 6A) Signal transduction N/A 
Immune 
response 
No change 
Q9H2W
1 
PICALM 
(Phosphatidyl
inositol-
binding 
clathrin 
assembly 
protein) 
AP2-dependent 
clathrin mediated 
endocytosis 
APP 
trafficking & 
Aβ clearance 
Synapse 
function & 
Endocytosis 
No change 
Q13492 
ABCA7 (ATP-
binding 
cassette sub-
family A 
member 7) 
Lipid homeostasis. 
Phagocytosis of 
apoptotic cells by 
macrophageS Aβ clearance 
Immune 
response 
& Lipid 
metabolism 
Increased 
Q8IZY2 
CD33 
(Myeloid cell 
surface 
antigen 
CD33) 
Mediates sialic acid-
dependent binding to 
cells Aβ clearance 
Immune 
response 
Increased 
P20138 
HLA-DRB1 
(HLA class II 
histocompati
bility antigen, 
DRB1-1 beta 
chain) 
Immunocompetence 
and histocompatibility N/A 
Immune 
response 
N/A 
P04229 
HLA-DRB5 
(HLA class II 
histocompati
bility antigen, 
DR beta 5 
chain) 
Immunocompetence 
and histocompatibility N/A 
Immune 
response 
N/A 
Q30154 
PTK2B 
(Protein-
tyrosine 
kinase 2-
beta) 
Induction of long term 
potentiation in 
hippocampus N/A 
Synapse 
function & 
Neural 
developme
nt 
N/A 
Q14289 
SORL1 
(Sortilin-
related 
receptor) 
APOE receptor. Binds 
LDL and RAP and 
mediates endocytosis 
of the lipids to which 
it binds 
APP 
trafficking 
Lipid 
metabolism
. Synapse 
function & 
Endocytosis 
Decreased 
Q92673 
SLC24A4 
(Sodium/pota
ssium/Calciu
Brain and neural 
development N/A 
Neural 
developme
nt. Synapse 
N/A 
Q8NFF2 
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Gene 
(Protein) 
Known function 
Potential 
Effects on 
APP and Tau 
Pathways 
Gene 
Expression 
UniProt 
ID 
m exchanger 
4) 
function & 
Endocytosis 
RIN3 (Ras and 
Rab 
interactor 3) 
Stimulates & stabilizes 
GTP-Rab5 in 
protein transport from 
plasma membrane 
to early endosome N/A 
Neural 
developme
nt. Synapse 
function & 
Endocytosis 
N/A 
Q8TB24 
DSG2 
(Desmoglein-
2) 
Mediates cell-cell 
junctions between 
epithelial and other 
cell type N/A N/A 
N/A 
Q14126 
INPP5D 
(Phosphatidyl
inositol 3,4,5-
trisphosphate 
5-
phosphatase 
1) 
Negative regulator of 
myeloid cell 
proliferation and 
survival N/A 
Immune 
response 
N/A 
Q92835 
MEF2C 
(Myocyte-
specific 
enhancer 
factor 2C) 
Controls synapse 
formation during 
activity-dependent 
refinement of synaptic 
connectivity and 
facilitates 
hippocampal-
dependent learning 
and memory N/A 
Neural 
developme
nt. Synapse 
function & 
Immune 
response 
N/A 
Q06413 
NME8 
(Thioredoxin 
domain-
containing 
protein 3) Ciliary functions N/A N/A 
N/A 
Q8N427 
ZCWPW1 
(Zinc finger 
CW-type 
PWWP 
domain 
protein 1) Epigenetic regulation N/A 
Neural 
developme
nt 
N/A 
Q9H0M
4 
NYAP1 
(Neuronal 
tyrosine-
phosphorylat
ed 
phosphoinosi
tide-3-kinase 
adapter 1) 
Brain and neural 
development N/A 
Neural 
developme
nt 
N/A 
Q6ZVC0 
CELF1 
(CUGBP Elav-
like family 
member 1) 
Regulates pre-mRNA 
splicing 
Mediates tau 
toxicity 
Neural 
developme
nt 
N/A 
Q92879  
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Gene 
(Protein) 
Known function 
Potential 
Effects on 
APP and Tau 
Pathways 
Gene 
Expression 
UniProt 
ID 
MADD (MAP 
kinase-
activating 
death domain 
protein) 
Long-term neuronal 
viability 
Mediates tau 
toxicity 
Neural 
developme
nt 
N/A 
Q8WXG
6 
FERMT2 
(Fermitin 
family 
homolog 2) 
Actin assembly and 
cell shape and 
mediator of 
angiogenesis 
Mediates tau 
toxicity 
Cytoskeleto
n & 
Axonal 
transport 
N/A 
Q96AC1 
CASS4 (Cas 
scaffolding 
protein family 
member 4) 
Docking protein in 
tyrosine-kinase 
signaling involved in 
cell adhesion and 
spreading N/A 
Cytoskeleto
n & 
Axonal 
transport 
N/A 
Q9NQ75 
PLD3 
(Phospholipa
se D3) 
Unknown 
APP 
trafficking 
and 
cleavage Unknown 
Increased 
Q8IV08 
TREM2 
(Triggering 
receptor 
expressed on 
myeloid cells 
2) 
Immune response, 
triggers production of 
inflammatory 
cytokines Aβ clearance Unknown 
Increased 
Q9NZC2 
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Appendix 2 
Solutions 
 50x TAE (Tris-acetate-EDTA buffer) 
To 600ml of deionised H2O add: 
 242g Tris Base 
 57.1ml Glacial Acetic Acid 
 100ml 0.5M EDTA (pH 8.0) 
Mix until the solutes have dissolved and adjust the volume to 1L with deionised H2O. Store at room 
temperature. 
 
 0.5M Ethylenediaminetetraacetic acid (EDTA) (pH 8.0) 
To 80ml of deionised H2O add: 
 14.612 g EDTA 
Mix until the solutes have dissolved and adjust the pH to 8.0 with Sodium hydroxide (NaOH). Adjust 
the volume to 100ml with deionised H2O. Store at room temperature. 
 
 3M Sodium Acetate pH5.2 
To 100ml of deionised H2O/80ml of deionised H2O add: 
 40.8g Sodium Acetate Trihydrate/24.6g Sodium Acetate Anhydrous 
Adjust the pH to 5.2 with glacial acetic acid. Store at room temperature. 
 
 Bromophenol Blue 
To 7ml of deionised H2O add: 
 0.025g Bromophenol Blue (0.25%) 
 3ml glycerol (30%) 
Mix and store at 4°C. 
 
 
